SCHEMBL7252847

SCHEMBL7252847

CC(C)CCc1cc[c]cc1CNC1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PABPC1 P11940 1/20 0.40
HTT P42858 3/20 0.39
KDM4E B2RXH2 3/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38
LMNA P02545 3/20 0.36
SLC2A1 P11166 1/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP1A2 P05177 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
USP2 O75604 1/20 0.35
SCN1A P35498 1/20 0.34
SCN2A Q99250 1/20 0.34
SCN3A Q9NY46 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7244714 0.99 PABPC1 (0.38) PABPC1HTTKDM4EKMT2AMEN1
SCHEMBL7243660 0.96 PABPC1 (0.35) PABPC1HTTKDM4EKMT2AMEN1
SCHEMBL7251009 0.93 HRH3 (0.31) PABPC1HTTKDM4EKMT2AMEN1
SCHEMBL7245360 0.80 BCHE (0.36) HTTKMT2A
SCHEMBL7250854 0.79 BCHE (0.31)
SCHEMBL5110872 0.78
SCHEMBL7252129 0.77 MEN1 (0.39) KMT2AMEN1CYP2D6CYP2C9CYP2C19
SCHEMBL7252845 0.76 PABPC1 (0.40) PABPC1HTTKDM4EKMT2AMEN1
SCHEMBL676980 0.76
SCHEMBL7244710 0.75 PABPC1 (0.38) PABPC1HTTKDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627624-B1 Agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, NEUROGEN CORPORATION 2003-09-30 US disclosed